Live
- A Guide to Temperature and Humidity Standards in Data Center Server Rooms
- Gadwal collector briefs on details of voters
- Jupally Krishna Rao takes part in Alampur rallu
- Bharath Prasad files 3rd Nomination
- Baisakh Month: A Time of Auspicious Beginnings and Sacred Festivals
- Oust BJD govt for overall development, says Shah
- Unveiling the Hidden Gems: Surprising Health Benefits of Garlic Peels
- Overcoming Sleep Struggles: A Comprehensive Guide to a Restful Night
- RTC bus hit the auto
- MLA Kuchukula Rajesh Reddy participated in the Birappa festival
Granules India recalls ranitidine tablets
Drug firm Granules India is recalling over 2.3 crore ranitidine tablets, used to treat ulcers of the stomach and intestines, from the US market, the latest report of the American health regulator said.
Hyderabad: Drug firm Granules India is recalling over 2.3 crore ranitidine tablets, used to treat ulcers of the stomach and intestines, from the US market, the latest report of the American health regulator said.
According to the Enforcement Report of the United States Food and Drug Administration (USFDA), the company is recalling 23,090,000 Ranitidine tablets USP 150mg, 10,000 count bag on account of "CGMP deviations: Impurity N-nitrosodimethylamine (NDMA) found in API".
CGMP refers to the Current Good Manufacturing Practice regulations. The voluntary ongoing recall is a class II recall, it added.
As per the USFDA, a class II recall is initiated in a "situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."
The tablets were distributed in Oregon, New York and New Jersey, the report said. NDMA is classified as a probable human carcinogen (a substance that could cause cancer).
It is a known environmental contaminant typically found in water and foods, including meats, dairy products and vegetables.
